falsefalse

ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 13

HERTHENA-Lung02 Trial: Exploring the Role of Patritumab Deruxtecan in Advanced EGFR-Mutant NSCLC

, , , ,

This episode summarizes the HERTHENA-Lung02 trial and examines the average duration of response to platinum-based chemotherapy in patients with advanced EGFR-mutated NSCLC who have previously undergone multiple lines of EGFR TKI therapy, discusses strategies for community oncologists to tackle diverse resistance mechanisms to third-generation TKIs, and evaluates the importance of tolerability in sparing platinum-based chemotherapy compared with using ADCs in subsequent treatment lines.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • Please summarize the HERTHENA-Lung02 trial. In your experience, what is the average DOR among your patients with platinum-based chemotherapy on or after treatment with at least 1 line of EGFR TKI therapy for advanced or metastatic EGFR-mutated NSCLC?
    • How might community oncologists address the diverse mechanisms of resistance to third-generation TKIs to optimize subsequent treatment aftermultiple lines of prior therapy for advanced or metastatic NSCLC with AGAs?
    • From a tolerability perspective, how important is sparing platinum-based chemotherapy in subsequent lines of therapy vs an ADC?
    x